NeOnc Technologies Reports No Revenue and Increased Losses in Latest Financial Filing

NeOnc Technologies Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for the third quarter, maintaining the same trend as the previous year. For the nine months ended September 30, 2025, total revenue was $39,990, a decrease from $63,000 in the same period of 2024. The company continues to operate at a loss, with a net loss of $8.6 million for the quarter and $46.6 million for the nine months, compared to $2.2 million and $9.6 million, respectively, in the prior year.

The financial performance reflects a substantial increase in operating expenses, which totaled $6.9 million for the third quarter, up from $2.2 million in the same quarter of 2024. This increase was primarily driven by a significant rise in share-based compensation, which amounted to $5 million for the quarter, as well as higher general and administrative expenses due to increased employee headcount and marketing efforts. For the nine-month period, total operating expenses surged to $44.6 million, compared to $5.1 million in the prior year, largely due to the same factors.

In terms of strategic developments, NeOnc Technologies has made notable progress in its clinical trials, particularly with its lead product candidate, NEO100, which is in Phase 2a trials for treating glioblastoma. The company has also expanded its research and development efforts, with total R&D expenses reaching $2.4 million for the nine months ended September 30, 2025, compared to $2 million in the same period of 2024. The company has been actively recruiting for its clinical trials and has initiated additional studies, including those for pediatric indications.

Operationally, NeOnc has seen changes in its financial structure, including an increase in cash and cash equivalents to $1.5 million as of September 30, 2025, up from $64,893 at the end of 2024. The company has financed its operations primarily through the sale of common stock, raising approximately $11.3 million from a private placement and additional funds from an equity purchase agreement. However, the company also reported a substantial accumulated deficit of $97.2 million, raising concerns about its ability to continue as a going concern without additional financing.

Looking ahead, NeOnc Technologies acknowledges the need for substantial additional funding to support its ongoing operations and product development. The company has expressed uncertainty regarding its ability to secure future financing on favorable terms, which could impact its operational capabilities and growth strategy. The management has indicated that it will continue to explore various funding avenues, including public or private equity offerings and potential collaborations, to sustain its business and advance its clinical programs.